Adarvez-Feresin_2024_Arch.Pharm.(Weinheim)__e2300581

Reference

Title : Inhibitory effect of galantamine and donepezil combination against cholinesterase: An in silico and in vitro study - Adarvez-Feresin_2024_Arch.Pharm.(Weinheim)__e2300581
Author(s) : Adarvez-Feresin CW , Ortiz JE , Pineiro MD , Parravicini O , Enriz RD , Garro AD , Feresin GE
Ref : Arch Pharm (Weinheim) , :e2300581 , 2024
Abstract :

This study aimed to evaluate the in silico and in vitro inhibitory effect of the combined use of galantamine (GAL) and donepezil (DON) against acetylcholinesterase and butyrylcholinesterase (BuChE) enzymes. In silico and in vitro cholinesterase analysis were carried out for GAL and DON alone and combined. Molecular modeling studies were carried out (docking analysis, molecular dynamics simulation, and quantum theory of atoms in molecules). Cholinesterase's inhibitory activities by modified Ellman's method and the drug combination effect using the Chou-Talalay method were assayed. GAL/DON combination showed the co-occupancy of the ligands in both enzymes through in silico studies. Regarding in vitro BuChE inhibition analyses, three of five combinations showed an interaction between GAL and DON at the threshold of additive affect (0.9 < CI < 1.1), with a tendency toward a synergistic effect for higher concentrations. This is the first report showing the efficacy of the GAL/DON combinations inhibiting BuChE, showing the importance of analyzing the behavior of different ligands when co-occupancy into the active site is possible. These combinations might be a possible therapy to improved efficacy, reduced doses, minor side effects, and high levels of the neurotransmitter in the synaptic space for Alzheimer's disease.

PubMedSearch : Adarvez-Feresin_2024_Arch.Pharm.(Weinheim)__e2300581
PubMedID: 38229212

Related information

Citations formats

Adarvez-Feresin CW, Ortiz JE, Pineiro MD, Parravicini O, Enriz RD, Garro AD, Feresin GE (2024)
Inhibitory effect of galantamine and donepezil combination against cholinesterase: An in silico and in vitro study
Arch Pharm (Weinheim) :e2300581

Adarvez-Feresin CW, Ortiz JE, Pineiro MD, Parravicini O, Enriz RD, Garro AD, Feresin GE (2024)
Arch Pharm (Weinheim) :e2300581